Talk about a return on investment.
In the four weeks since two biopharma companies merged to form Korro Bio, the new stock has more than quadrupled. And a slew of high-profile hedge funds are among the biggest beneficiaries.
On November 3, Korro Bio merged with Frequency Therapeutics and now operates under the name Korro Bio.
